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Long-term survival in metastatic melanoma patients with leptomeningeal disease 
treated with intrathecal interleukin-2 
 
Isabella Claudia Glitza Oliva, M.D., Ph.D. 
Advisory Professor: Patrick Hwu, M.D. 
 
BACKGROUND: Metastatic melanoma patients with leptomeningeal disease (LMD) have an 
extremely poor prognosis and a paucity of effective treatment options. We assessed the safety 
and efficacy of intrathecal interleukin-2 (IT IL-2) in metastatic melanoma patients with LMD.    
METHODS: We reviewed the outcomes of 43 consecutive metastatic melanoma patients with 
LMD who were treated with IT IL-2 from 2006 to 2014 in a Compassionate Investigational New 
Drug Study. All patients had evidence of LMD based on cerebrospinal fluid (CSF) cytology, 
radiology, and/or surgical pathology. IL-2 at a dose of 1.2 mIU was administered intrathecally 
via Ommaya reservoir up to 5 times per week in the inpatient setting for 4 weeks; patients with 
good tolerance and clinical benefit received maintenance IT IL-2 every 1 to 3 months thereafter.    
RESULTS:  The median age of the patients was 46.7 years (range 18-71); 32 (74%) were male; 
31 (72%) had positive CSF cytology, and 39 (91%) had radiographic evidence of LMD.   Median 
overall survival (OS) from initiation of IT IL-2 was 7.8 months (range, 4.7-16.3 months), with 1-, 
2-, and 5-year OS rates of 36%, 26%, and 13%. The presence of neurological symptoms (HR 
2.1, p=0.03), positive baseline CSF cytology (HR 4.1, p=0.001) and concomitant use of targeted 
therapy (HR 3.0, p=0.02) were associated with shorter OS on univariate analysis.  All patients 
developed symptoms due to increased intracranial pressure. There were no treatment-related 
deaths. 
CONCLUSION: IT IL-2 treatment is safe and achieves long-term survival in a subset of 
metastatic melanoma patients with LMD.  
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Chapter I 
INTRODUCTION 
Background: 
The spread of cancer to the central nervous system (CNS) is a devastating complication of 
multiple tumor types. The solid tumors that most often metastasize to the CNS are lung cancer, 
breast cancer, and melanoma.  As melanoma has a much lower incidence compared to breast 
or lung cancer, melanoma has the highest risk of CNS metastasis of the common cancers.  
CNS metastases are diagnosed clinically in up to 60% of metastatic melanoma patients, and 
evidence of CNS involvement is identified in up to 80% of patients at autopsy. 1  
 
The CNS is a frequent site of treatment failure for melanoma, including treatment involving 
recently approved targeted and immune therapies.  Multiple studies have demonstrated an 
average of 4 months of median survival time after the diagnosis of melanoma CNS metastasis. 
1-2  Patients with parenchymal brain metastases have a number of treatment options including 
surgery, whole-brain radiotherapy (WBXRT) and stereotactic radiosurgery (SRS).  New 
systemic therapies, including the BRAF inhibitor dabrafenib and the immune checkpoint 
inhibitors ipilimumab and pembrolizumab, have also demonstrated efficacy in clinical trials for 
metastatic melanoma patients with parenchymal brain metastases.  In contrast, there are very 
few treatment options for patients with leptomeningeal disease (LMD), and these patients 
have extremely poor outcomes.  The leptomeninges consist of a total of 3 layers of meninges 
that cover the parenchymal brain and spinal cord. The first layer is called dura mater, which is 
made of connective tissue. The second layer in the middle is referred to as the arachnoid, which 
is a fairly thin layer that resembles a spider web, with multiple strains attaching to the inner 
layer, named pia mater. This space formed between the most inner layers, the arachnoid and 
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the pia mater,  contains cerebrospinal fluid (CSF) and is comprises the subarachnoid space 
which alos contains and houses all the blood vessels. 
Any cancer can metastasize to the leptomeninges, but certain cancer types are more likely to do 
so. In breast cancer, the reported incidence of LMD has been up to 5%, in lung cancer in up to 
25%, and in melanoma in 22-46%. 3 No effective treatment options for these patients, and that 
the NCCN guidelines only recommend palliative radiotherapy and best supportive care, the 
development of more effective treatments for LMD from melanoma is a critical unmet need. 
 
 
Diagnosis of LMD 
Recent reports have suggested that the incidence of leptomeningeal disease is rising due to the 
fact more effective systemic therapies are available for patients with metastatic disease, leading 
to a longer overall survival. 4  However, as patients live longer there can be subsequent 
metastatic spread to the central nervous system including the leptomeninges.  
 
It is possible that the increased incidence of LMD is also due to general higher awareness of the 
clinician, combined with increased use of neuroimaging, specifically gadolinium-enhanced MRI 
of the brain and spine, which is one of required test for disease confirmation. The MRI should 
consist of a postcontrast T1 weighted image, as well as postcontrast FLAIR imaging. These two 
sequence combined are felt to be the most sensitive to detect LMD. 5-6 LMD can present on MRI 
imaging in different ways, and can vary from a diffuse leptomeningeal enhancement to bulky or 
nodular tumor foci (Fig 1). The most common presentation though is the more diffuse 
enhancement seen within the horns of the ventricles, as sometimes referred as zuckerguss 
(German for sugar coating).  It is important to note that a normal MRI never excludes the 
diagnosis of LMD. Furthermore, the sensitivity of an MRI has been reported to range greatly 
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from 22 to over 90 %, but any irritation of the leptomeninges can result in an enhancement 
observed on the MRI, therefore should be obtained prior to lumbar puncture. 7 
 
   
Fig 1: Radiographic findings of LMD: diffuse leptomeningeal enhancement, “zuckerguss” of the 
ventricle horns and nodular tumor foci within the ventricle 
 
The gold standard for diagnosis of LMD remains CSF analysis showing tumor cells, which is 
termed “positive CSF cytology.”  CSF analysis has several limitations. While the specificity is 
reported to be above 80%, the sensitivity of just 1 CSF analysis remains low and is often quoted 
to be around only 50%. In addition, CSF sampling is normally fairly low-volume, and improper 
specimen handling can again lead to inaccurate results due to cell degeneration. Other 
abnormalities observed in the CSF can be generally seen in the majority of cases with LMD. 8 
These range from an increased white blood cell count, increase protein levels, decreased 
glucose levels to increased opening pressures.  
 
A significant number of patients report symptoms and signs of neurological impairment at time 
of LMD diagnosis. Depending on the location and extent of LMD, these symptoms can include 
headaches, mental status changes, and nausea and vomiting. If cranial nerve involvement is 
present, patients most often describe diplopia, visual loss, and hearing loss as well as facial 
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numbness, or other focal neurological deficits. 3 LMD affecting the spinal axis can lead to lower 
motor neuro weakness, paresthesias, back and/or neck pain, radicular pain and bladder and 
bowel dysfunction. Given that up to 80% of patients have concurrent parenchymal brain 
metastases, it is important to distinguish the symptoms caused by LMD from those due to brain 
metastases, as well as complications of any other treatments the patients are currently 
receiving. 9-10  
 
Finally, due to the fact that the diagnosis of LMD remains challenging, new approaches are 
being tested. Cell free DNA (cfDNA) and circulating tumor cells are being used to monitor 
treatment response in the blood, and are an exciting approach to diagnose metastatic disease 
prior to evidence on imaging. This approach was recently translated into the monitoring of levels 
of cfDNA in the CSF of a patient with metastatic BRAFV600E mutant melanoma and 
LMD.11  The patient was initiated on dabrafenib and trametinib and responded to therapy with 
resolution of his previously reported headaches, nausea, and vomiting after 2 months of 
treatment. Unfortunately, his symptoms returned 3 months later, and he required neurosurgical 
intervention. However, he underwent 9 CSF samplings over a period of six-month. Interestingly, 
the fraction of mutant cfDNA gradually decreased from 53% at time of diagnosis to being 
undetectable at time of being symptom-free. When the patient developed recurrent symptoms, 
the mutant cfDNA was attempted again at high levels. Therefore it was felt that this approach 
could be used to diagnose and monitor therapeutic response after treatment initiation. 
 
Survival and LMD 
Patients with CNS metastasis in general have a median overall survival that is typically 
measured in months, but patients with evidence of LMD have the worst prognosis among all 
melanoma patients who suffer from metastatic disease. A cohort of 743 stage IV patients was 
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reviewed, and found that 330 were diagnosed with brain metastasis at one point during their 
melanoma treatment history. The median survival of all patients with CNS metastasis was 4.65 
months. Patients diagnosed after 1996 had a slightly increased OS with 5.92 months (HR 0.6-
0.94, p+0.01), but age >or < 65 did not have an impact on outcome. Patients who developed 
LMD (n=11) had the worst overall survival with a median of only 1.22 months, and fared even 
worse than patients who were diagnosed with >3 brain metastases (3.52 months median OS). 1   
Other studies have confirmed this poor outcome and therefore underline the need for clinical 
trials and better treatment strategies for these patients.  A recent study including 39 patients 
with LMD from melanoma (diagnosed 2010-2015) reported a median OS for the entire cohort of 
6.9 weeks. 12 Patients who received no further treatment for LMD had a median OS of only 2.9 
weeks, with an increase to 16.9 weeks in patients who received treatment.  A second 
retrospective analysis of 55 patients described a median OS of 9.7 weeks. 13 Researchers at 
MD Anderson Cancer Center reported a median OS of 10 weeks in a large retrospective study 
of 110 patients diagnosed between 1944 and 2002, with a 1-year survival of 7%, and a 2-year 
OS of only 3%. 14  
I recently reviewed the clinical features, treatments, and OS of 178 melanoma patients 
diagnosed with LMD by CSF cytology or MRI between 2000 to 2015 at the UT MD Anderson 
cancer center, which represents the largest and most temporary patient cohort available for 
analysis. The diagnosis was based positive on positive CSF cytology in 48% of patients, 
highlighting that in a large number of cases the diagnosis of LMD is made by CNS imaging. The 
reported median age at diagnosis was 51 , with a high male predominance (74%). 39% had 
elevated LDH, and most patients had concomitant brain (76%) and extracranial (74%) 
metastases.  Neurological deficits were reported in 47% patients. Median OS from LMD 
diagnosis was 3.0 months.  
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Prognostic factors for survival in LMD patients 
While it is known that patients with LMD from melanoma have the worst prognosis of all 
metastatic melanoma patients, very few studies have identified prognostic markers for survival. 
A previous retrospective study of 110 patients at MD Anderson collected the following 
information for analysis: 14  Patient specific demographics as well as tumor specific factor like 
thickness, subtype of primary lesion and its location, time interval between diagnosis of primary 
melanoma and LMD, serum lactate dehydrogenase (LDH), symptoms and signs of LMD, CSF 
specific information, location and number of concomitant parenchymal brain metastasis and 
treatments received.  This study identified elevated serum LDH to be associated with poorer 
survival, but elevated LDH was probably mainly a marker of significant extracranial disease 
burden. Of note, number of extracranial metastasis and their location were not included in the 
analysis due to differences in reporting of the extracranial tumor burden. Interestingly, patients 
with concomitant brain metastasis did not have significantly worse outcomes than patients 
without other CNS metastasis, and  the amount of LMD tumor burden was not associated with 
survival (p=0.11).  Radiographic evidence of LMD or the presence of positive cytology had no 
impact on overall survival (10 weeks).  Patients who received therapy directed at their LMD 
derived benefit, and this was reported for all three treatment modalities evaluated [radiation (HR 
= 0.5, p = 0.0015), systemic chemotherapy (HR = 0.6, 95% CI = 0.4, 0.9, p = 0.028), and  direct 
Intrathecal therapy (HR = 0.5, 95%, p = 0.0001)].  All these patients were diagnosed between 
1944 and 2002, and therefore not treated with currently available targeted therapies and 
immunotherapies. After multivariate analysis, primary melanoma located on the trunk of the 
patient appeared to be associated with worse outcome (hazard ratio [HR] = 2.0, 95% CI = 1.0-
3.8, p = 0.035), which is consistent with reports associating the location of the primary tumor 
with the development of metastatic CNS disease.  
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As with extracranial disease, poor performance status as time of LMD diagnosis has been 
associated with significantly worse outcomes. 3, 15 Other studies found that an elevated LDH at 
LMD diagnosis, time between primary tumor and development of LMD were also associated 
with worse survival. 12, 14, 16  
Elevated CSF protein levels correlated with poor prognosis in multiple studies (Table 1).  This is 
defined as a CSF protein concentration >50mg/dL. These findings are often in conjunction with 
a low CSF glucose count and elevated opening pressures.  
Table 1: Factors associated with survival in patients with LMD  
Author Number 
of 
patients 
Melanoma 
only 
Diagnosed OS Associated with poor survival  
Foppen12 39 Yes 2010-2015 6.9 weeks 
(2.9 for 
untreated 
vs 16.9 for 
treated). If 
treated with 
systemic 
therapy +/- 
RT, 21.7 
weeks 
• Elevated serum LDH and S100B at diagnosis 
Harstad14 110 Yes 1944-2002 10 wks • Location of primary melanoma on the trunk (HR 2.0 
(p = 0.035) 
• Intrathecal chemotherapy had positive effect on 
survival, while radiation and systemic therapy did 
not impact either survival nor were reported to have 
detrimental effects.  
Oechsle17 2/135 No 1989-2005 10 wks 
overall, 0.9 
months 
melanoma 
• Differences in type of solid tumor, with lung an 
melanoma having the highest risk of death 
• Time interval between initial tumor diagnosis and 
the development of LMD being less than 1 year, 
patient s younger than 50, decreased performance 
status Karnofsky, use of systemic therapy and lack 
of clearing of CSF tumor cells observed. 
Waki18 2/89 No 1997-2005 51 days • Decreased overall performance status (HR: 1.72 
(95% CI, 1.04-2.86) P = 0.04)  
• MRI evidence of leptomeningeal diseae (HR: 1.82 
(95% CI, 1.11-2.98) P = 0.02)  
Herrlinger16 21/155 No 1980-2002 4.8 months, 
4.7 months 
for 
melanoma 
• Advanced patient age of over 60  
• Increased CSF protein levels  
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Palma19 0/50 No 2001-2010 For patients 
who 
received 
specific 
treatment,  
21.2 weeks 
vs. 6.38 
weeks for 
patients 
receiving 
supportive 
care 
only 
• Decreased overall performance status 
• Increased CSF protein levels  
• Time from diagnosis of primary tumor to diagnosis 
of LMD  
Hyun15 0/519 No 2005-2014   • Decreased overall performance status 
• Increased CSF protein levels (>50 mg/dl) 
• lung cancer patients with LMD in general had a 
better outcome 
 
While LMD directed treatment in general is felt not be very beneficial for these patients, there is 
some evidence that therapy can improve OS, and better survival was observed in patients 
receiving intrathecal and systemic therapy. 13, 17 The largest and most contemporary analysis of 
prognostic factors also showed that the median OS was improved for treated patients (8.2 
months for patients treated with targeted therapy, 7.1 months for IT, 4.7 months for 
chemotherapy, and 3.7 months for IMT), while Positive CSF cytology (HR 2.26, CI 1.27-4.00, 
p=0.006), presence of neurological deficits (HR 2.21, CI 1.60-3.05, p<0.0001), uncontrolled 
systemic disease (HR=1.68; CI1.16-2.44, p-0.006) and elevated LDH (HR 1.44, CI 1.04-2.00 p= 
0.03) were associated with shorter OS per Cox proportional hazard regression analysis. 
The NCCN recommends that patients with leptomeningeal disease are being stratified based on 
several factors. Patients which are considered “poor risk” have a low KPS score, multiple and 
potentially serious neurological deficits, uncontrolled systemic disease or significant overall 
disease burden, bulky CNS disease and encephalopathy. Patients who were categorized as 
“good risk” have a good performance status, no major neurological deficits, and either controlled 
or limited systemic disease, for which treatment options are available.  
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Treatment for leptomeningeal metastasis from melanoma 
Treatment for leptomeningeal disease is palliative in nature, with the main goal of providing 
symptom relief. As per NCCN guidelines, the main treatment modalities include systemic 
therapy or radiation.  Surgery is seldom considered due to the disseminated nature of the 
disease but neurosurgery is required for the placement of an intraventricular catheter or further 
symptom management associated with hydrocephalus or increased intracranial pressure. 
Whole brain radiation (WBRT), with the average dose of 30 Gy, can be used for symptom 
management and is part of the NCCN recommendations for patients with LMD and good 
performance status. It has to be noted, that it rarely leads to significant neurological 
improvement. On occasion, involved field radiotherapy is being used to treat symptomatic 
disease or bulky disease, specifically if it is associated with significant pain. 3 In an attempt to 
develop a prognostic index aiding in predicting outcomes for melanoma patients with brain 
metastasis, 112 patients with CNS involvement who had received WBRT were analyzed. 
Presence and extent of extracranial disease had significant impact on survival, but patients with 
LMD present (n=7) had also significantly worse outcomes (HR 3.13 (1.41–6.95)). To date, it 
remains unclear whether WBRT has any impact on OS, even when LMD is present or in tumors 
that are more radiosensitive than melanoma. 17, 20  
Historically, systemic chemotherapy has not demonstrated consistent clinical benefit in patients 
with LMD. Case reports have noted one melanoma LMD patient with a complete response on 
the combination of temozolomide (TMZ) with cisplatin, and another patient showing a complete 
radiological response as well as a dramatic improvement in quality of life for about 10 months 
after initiation of TMZ. 21-22  The largest prospective clinical trial using oral TMZ in 19 patients 
with LMD associated with solid tumors included 1 patient with melanoma, who did not benefit. 23  
In a small prospective clinical trial of nine melanoma patients, IT liposomal cytarabine was used 
initially, and three patients went on to receive  IT thiotetraethylenepentamine, with concurrent 
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systemic treatment (TMZ (n=3), fotemustine (n=5) or carboplatin (n=1). 24 The median OS was 8 
weeks (range=1-168 weeks), with two patients responding and achieving prolonged survival 
(104 weeks). Survival of over 1 year has also been reported in a melanoma LMD patient treated 
with the combination of IT liposomal cytarabine, systemic TMZ, and WBXRT. 25   
Targeted therapy in the management of leptomeningeal melanoma metastasis has not been 
assessed in a prospective clinical trial, but there is increasing evidence that these drugs can 
provide benefit to patients with parenchymal CNS metastasis. 26  It has been reported that the 
distribution of vemurafenib, a BRAF inhibitor, was 3-logs lower in the CSF when compared to 
plasma concentration. Dabrafenib, a second BRAF inhibitor with regulatory approval for the 
treatment of metastatic melanoma appears to have higher penetration. 27-28 Case reports have 
shown that some patients appear to derive benefit from this treatment. 29 
The check-point inhibitor ipilimumab and pembrolizumab have demonstrated clinical responses 
and favorable survival outcomes in prospective clinical trials in melanoma patients with 
parenchymal brain metastasis. 30-33 In a non-randomized phase II trial ipilimumab administration 
led to a response rate of 15.7% for Cohort A (neurologically asymptomatic, no concurrent 
corticosteroids) and 5% for Cohort B (neurological symptoms and requiring a stable dose of 
corticosteroids). The overall response rate, 2-year survival rates (Cohort A 26%, Cohort B 10%) 
and safety in this study were similar to what has been reported in melanoma patients without 
brain metastases who were treated with ipilimumab. 34 Konstantinou  and colleagues reported a 
brain control rate of 16% and a response rate of 8% in 38 melanoma patients with CNS 
metastases who received with ipilimumab as part of the extended access program. 35 
Pembrolizumab, an anti-PD1 antibody, showed a 22% brain metastasis response rate in a 
recently reported open-label phase-2 trial. 33Additional clinical trials are ongoing with other-FDA-
approved targeted therapy and immunotherapy combinations (NCT02308020, NCT00338377). 
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34  However, all of those completed and most of the planned trials have excluded patients with 
LMD (Appendix, Table 7, 8).  
 
Intrathecal immunotherapy 
Intrathecal immunotherapy approaches have been tested in patients with melanoma LMD since 
the early 1990s. The idea of using an intrathecal approach stemmed from observation that 
many drugs do not cross the brain blood or brain-CSF barrier in a meaningful way, and that 
intrathecal administration was required to achieve meaningful CSF drug levels.  Furthermore, 
long term remissions were observed in a subset of patients treated with intravenous interleukin-
2, providing initial evidence that immunotherapy can result in significantly improved outcomes. 
One of the first intrathecal trials used interferon alfa. In this phase II trial, 20 patients with LMD 
from different solid and hematologic tumors received recombinant interferon alfa via Ommaya 
every other day for 4 weeks, which was considered an induction. 36 Only 2 of the patient's and 
this cohort had melanoma LMD, while the majority of patients had other solid tumors. The 2 
patients treated with LMD for melanoma both progressed very fast, with progression seen after 
only to 4 weeks of treatment. Interestingly in the other treated patients, responses lasted up to 
40 weeks, with a median duration of 16 weeks. Patients with hematologic malignancies and 
LMD head is significantly better outcome then patients with solid tumors. No other predictive 
factors for response were found, with age, performance status at treatment initiation, the 
addition of radiotherapy, systemic chemotherapy not altering outcome.  An additional case 
report suggested stability of LMD in a patient receiving IT INF, but the patient passed after 3 
months of IT treatment due to malignant pericarditis. 37 
 IT interferon alpha-2b was reported to improve symptoms in one patient, while others 
progressed during treatment. 36-37 Previously published data from our institution and single-
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patient reports from other centers have shown that IT IL-2 can achieve prolonged OS in some 
patients, associated with significant toxicities. 38-41 
 
Interleukin-2 (IL-2) 
The cytokine interleukin 2 (IL-2) is mainly secreted by antigen-stimulated CD4+ T cells. It 
supports the proliferation and activation of CD8+ T cells as well as increasing the cytolytic 
capacity of natural killer cells (NK). 42 When given systemically, IL-2 administration leads to 
release of cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), 
interleukin- 6 (IL-6) and interferon- gamma (INF-γ). These cytokines are responsible for the 
symptoms mimicking influenza infection and contributing to the capillary leak syndrome, leading 
to fluid retention and hypotension. The earliest clinical trial dates back to the 1980s, when HD 
IL-2 was tested in generally small cohorts of patients. The largest trial included 270 patients, 
with an overall response rate of 16.5%, including a 6% complete response (CR) rate. 
Importantly, durable responses were reported, which were observed in patients who had a 
complete response to treatment or who were converted to “complete response” by surgery for 
their residual disease. 43 Subsequent trials showed response rates between 5-27%, and 
attempts to improve the response rates with either interferon or lymphokine activated killer cells 
did not result in better outcome.  While highly toxic, with the most common side effects being 
nausea/vomiting, diarrhea, hypotension, thrombocytopenia, renal and hepatic dysfunction, some 
patients never experienced melanoma re-occurrence. 44 These “cures” were particularly seen in 
patients in who did not experience progression of disease, or who had an ongoing response for 
more than 30 months. 45 While HD IL-2 has been mainly used in patients without active CNS 
metastases, some case reports hint that its use might be safe in a patient population with active 
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brain metastasis. Eight patients were treated with HD interleukin-2 and radiation therapy, and 
the median OS was 6.7 months. 46 
 
Intrathecal IL-2 
The use of intrathecal IL-2 (IT IL-2) dates back to the 1980s. This was based on data evaluating 
the ability of recombinant IL-2 to permeate the CSF- Blood barrier. 38, 40, 47-49  Twelve cancer 
patients without CNS involvement received I.V. administered IL-2, and changes in the levels of 
CSF IL-2 were monitored via lumbar punctures. IL-2 was first identified in the lumbar CSF 4-6 
hours after the systemic dose, and a subsequent increase of the observed levels were observed 
over the next 2-4 hrs until a stable level of 3 to 9 U/ml was reached. After the last systemic 
dose, levels returned to less than 0.1 U/ml by 10 hours. While these levels were believed to be 
possibly sufficient for lymphokine-activated killer (LAK) cells activity, it also gave rise to giving 
IL-2 directly into the ventricle. Serum levels of intravenous injection with IL-2 showed a rapid 
increase in the concentration, with a reported mean peak value of 55U/ml. Clearance was 
shcieved rapidly, consistent with a previously reported 7 minute half-life.  
In these early case reports, IT IL-2 was used in combination with LAK cells and given to a 
patient with malignant glioma. 48  In 1991, another case report described the use of continuous 
intraventricular infusion of IL-2 for 5 days, again combined with LAK. 50 Intracranial pressures 
rose to a maximum to 80 mmHg, but it was also noted that within 2 days after last dose of IT IL-
2, the CSF pressures normalized. Interestingly, the leukocyte concentration and composition 
changed during the course of treatment. The initial cell count after LAK infusion and IL-2 was 
202/mm3, with 15% being monocytes, 19% lymphocytes, and 66% neutrophils. The cell count 
diminished after 4 days to just 8/mm3. Prior to the second dose of IL-2, the CSF cell count was 
5/mm3, with 40% of lymphocytes and 60% monocytes. During the second cycle of 
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interventricular ventricular IL-2, the CSF cell count rose to 16/mm3, with 76% being 
lymphocytes, 21% granulocytes, and 3% monocytes.  
Eleven patients with LMD from melanoma and adenocarcinoma of the lung were treated with 
intraventricular injection of IL-2. 51 All patients had an Ommaya reservoir in place, and CSF 
samples were collected at different intervals between 0 and 24 hours. It was found that IL-2 
levels gradually decreased during the first 24 hours after injection, with an average half-life 
between 4 and 8 hours. It was also observed that IT IL-2 administration led to an increase in 
TNF- α, IL-1β, IL-6, INF-γ, as well as soluble IL-2 receptor (IL-2R). These cytokines also had 
different peaks after IT IL-2 administration.  For example, the earliest cytokines peaked at 2-4 
hours and at 4-6 hours, respectively, TNF- α and IL-6. IL-1β, INF-γ and IL-2R peaked between 
6-12 hours. Of note, all cytokines returned to nearly baseline between 12 and 24 hours; 
however, a slightly elevated level of the IL-2 receptor was observed.  
As in the previously described case reports, IT IL-2 led to an increase in CSF leukocyte and 
lymphocyte count. Neutrophils were the predominant cell population during the first 24 hours, 
and a decrease of the overall cell count in the CSF was observed at 36-48 hours. 
Simultaneously, an increase in total lymphocyte count was observed. Most patients also 
continued to have an elevated CSF lymphocyte count for 7-10 days during the subsequent 
treatment courses. The authors felt that the late appearance of lymphocytes and the lack of 
cytokine-producing cells at the initial time from CSF analysis suggested that there must be a 
local source for the observed cytokine production.  
The early intrathecal IL-2 case reports did notice significant toxicities. For example, one patient 
experienced significant tachycardia, hypertension and changes in mental status 11 hours after 
the first dose of IT IL- 2. When an Ommaya tap was performed, his intracranial pressure was 
elevated, but his symptoms were improved after removal of CSF. After 4 days, all his 
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neurological toxicities had resolved. Similar toxicity was seen despite 50% of dose reduction. 
Patient did not achieve a response to therapy. 38 Another patient overall was felt to tolerate the 
continuous IL-2 well, but had increased intracranial pressures that responded to CSF removal. 
While they did not mention in detail the side effects, it has to be noticed that his intracranial 
pressures were as high as 80. In regards to efficacy it appeared that the patient's neurological 
status did not improve, with ongoing paraplegia, but systemic disease progression, finally 
leading to the patient passing. 50 In the larger study of 12 patients evaluating the penetration of 
IL-2 across the blood CSF barrier patients received IL-2 via IV, but still experienced mentation 
change during treatment. Interestingly, CSF IL-2 levels in the patient with the highest level did 
not result in any change in mental status, and elevated albumin quotient did not seem to be 
associated with change in mental status or toxicity. 52 No efficacy was recorded. The most 
detailed side effect monitoring was performed in a 4 patient's study suffering from LMD in 1988. 
47 Only one patient experienced significant side effects, which were mainly bitemporal 
headaches during administration of IL-2. During the last administration he also suffered from a 
seizure, which was only focal, and stopped with the termination of the injection. His CSF 
analysis at this time did not show major disturbances of the blood CSF barrier. Specifically, 
fever chills or anaphylactic reactions were not observed in this trial. All patients did experience 
an increase in their CSF leukocyte count.  
 
Patient characteristics and biomarkers associated with response to immunotherapy  
While encouraging results have been seen with the use of immunotherapy for patients with 
metastatic melanoma, predicting response remains difficult, and little is known about robust 
clinical characteristics and biomarkers associated with response to immunotherapy. The first 
immunotherapy regularly used for metastatic melanoma patients was high dose interleukin- 2 
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(HD IL-2), which was FDA approved in 1998. While the treatment with HD IL-2 is highly toxic, 
requiring hospitalization and ongoing cardiac monitoring, the success rate is fairly low compared 
to the era of targeted therapies and immune checkpoint inhibitors. Therefore, it is even more 
important to find prognostic or predictive biomarkers for treatment response.  
Retrospective analyses have shown a correlation between degree of thrombocytopenia and 
clinical benefit from HD IL-2 in patients with either stage IV renal cell cancer or melanoma. 53  In 
addition, the total number of  HD IL-2 doses received (33.0 versus 18.0, p =0.001), number of 
total cycles of HD- IL- received (6.0 versus 2.0, p <0.001) and development and frequency of 
autoimmune-based side effects (p = 0.049) were associated with better outcomes. Another 
group uncovered that a cluster of 11 soluble biomarkers were associated with survival. 54 
Patients with higher VEGF and fibronectin levels were much likely not to respond to HD IL-2, 
and represented independent predictors of non-response. Baseline elevated absolute 
lymphocyte count (ALC) at the start of cycle 1, as well as the ALC peak during therapy was not 
associated with an improved outcome. 53  
However, another clinical report showed that clinical responses in melanoma patients treated 
with the immune checkpoint blocker ipilimumab were associated not only with an increase in 
ALC, but also the absolute T cell count and the absolute number of activated T cells in 
peripheral blood. 55 Neutrophil to lymphocyte count ratio after 2 cycles of CTLA4 blockade was 
associated with outcome, and used in the development of a prognostic model for overall survival 
after 2 doses of ipilimumab. Correlation between the development of immune-related adverse 
events (irAE) and greater likelihood of achieving an objective tumor response (p=o.ooo4) was 
described in the early reports of ipilimumab. 56 The clinical characteristic of elevated LDH was 
also associated with worse prognosis in CTLA_4 treated patients.57 
Recent advances have shed some light into biomarkers of response for patients receiving 
checkpoint blockade. For example, it has been shown that in increase in neoantigen burden is 
17 
 
correlated with significant improved outcomes in adenocarcinoma of the lung. 58 Furthermore, 
gene expression profile varied between patients who respond and don't respond in this study. 
Genes that were different included PDL 1, pro-inflammatory IL-6 as well as genes linked to 
antigen presentation, T-cell migration and affect her T-cell function, specifically INF-γ, 
granzymes as well as LAG-3.   
With the event of anti-PD1 and anti-PDL-1 agents used as the mainstay of anti- melanoma 
therapy, biomarkers for appropriate patient selection are needed. It appears that PDL-1 
expression is required for therapeutic activity, and some clinical trials suggested that positive or 
high PDL-1 expression in the tumor was associated with improved response and OS.59-60 PDL-1 
expression analysis faces though multiple technical challenges due to a multitude of different 
antibodies and cut-off % used to score the cells. Furthermore, it is important to mention that 
patients without appreciated PDL-1 expression still derived benefit from treatment with anit-PD1 
agents, though at a lower rate.61,62   
Another report evaluated a cohort of metastatic melanoma patients who received either 
checkpoint blockade with CTLA 4 or anti-PD1. These patients were then separated into groups 
who were considered non-responders to therapy and responders.63 Patients who were 
considered a responder were defined as having radiographic evidence of absent disease, stable 
disease, or decreased tumor volume for at least 6 months. Interestingly, early on- treatment 
biopsies evaluated by IHC found a difference in the density of CD8+ T cells in responders 
versus nonresponders receiving CTLA 4. For patients responding to PD1 blockade, a 
statistically significant difference in the density of CD8+, CD3+, and CD45RO+ T cells in the 
treatment samples were observed. To monitor for similar differences in the invasive tumor 
margins, IHC evaluation was done to compare tumor center versus tumor periphery.   While no 
significant difference in the density of CD8+ T cells and responders versus nonresponders, was 
seen, a higher ratio of CD8+ T cells in the tumor center versus the tumor margin observed. The 
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same group of researchers also evaluated the difference in gene expression profiling of the 
longitudinal biopsies, and showed 411 significantly differentially expressed genes and 
responders, mostly upregulated, as compared to nonresponders. It appeared that CTLA4 
blockade and PD1 blockade varied slightly in which genes were upregulated. Taken together, 
these studies offered new understanding of the mechanisms of therapeutic resistance involved 
an immune checkpoint blockade treated patients. This will be specifically important when 
developing new strategies to overcome resistance. 
While this represents exciting data for extracranial disease, these tests cannot be performed in 
a similar fashion for leptomeningeal disease, where no tumor tissue is readily available, and 
testing has to be performed on few melanoma cells found in the CSF. However, cfDNA, flow 
analysis and NGS sequencing are all new approaches that might increase our understanding of 
the CSF as a microenviroment. To date, for patients with LMD, the only CSF finding associated 
with poor survival is an elevated CSF protein level at diagnosis, but virtually nothing else is 
known about how other factors, like opening pressure at time of Ommaya tap and CSF WBC or 
ALC affect prognosis, or how these can be used to predict patients with poor survival. 
 
Hypothesis: 
In this proposal, we will test the hypothesis that intrathecal immunotherapy with interleukin-2 
can be a safe and effective therapy for patients with LMD from melanoma, and that clinical 
outcomes will correlate with clinical and immunological features.  
In order to test this hypothesis, and ultimately to develop more effective therapies for patients 
with LMD based on these results, we will: 
AIM 1 Evaluate the safety and efficacy of IT IL-2.  
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AIM 2 Examine the clinical patient characteristics and evaluate how these factors are 
associated with outcomes.  
AIM3:  Examine CSF specific features at baseline and evaluate how the observed changes with 
IT IL-2 treatment correlate with clinical benefit.  
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CHAPTER II 
METHODS 
Patient selection: 
This analysis included the outcomes of 43 consecutive metastatic melanoma patients with LMD 
treated with IT IL-2 at The University of Texas MD Anderson Cancer Center under an ongoing 
Compassionate Investigational New Drug Study. All patients started IT IL-2 treatment after 
August 2006; the last three patients initiated treatment in July 2014.  The time of data cutoff was 
November 15, 2015.  The diagnosis of LMD was established by cytopathological analysis of 
CSF, neuroradiological imaging with MRI, surgical/pathology report, or a combination of these 
diagnostic modalities. All patients were required to have a baseline MRI of the brain and entire 
spine and placement of an Ommaya reservoir (or shunt) with flow confirmation via radionuclide 
study prior to the start of treatment. IT IL-2 therapy was approved by the U.S. Food and Drug 
Administration (FDA) as a Compassionate Investigational New Drug (CIND), and all patients 
provided written consent for treatment.  Previous systemic therapies, including chemotherapy, 
immunotherapy, or radiation therapy to the brain or spine, were allowed.  Patients who were 
believed to be deriving clinical benefit from such therapies prior to the initiation of IT IL-2 could 
receive them concomitantly with the treatment at the discretion of their treating physician.  
Ommaya Placement 
All patients required the placement of an Ommaya reservoir prior to the first dose of IT IL-2. 
Briefly, the placement of an Ommaya, typically performed in less than an hour, is performed as 
following: After appropriate positioning the area of the scalp is cleaned and shaved, and a small 
round incision is made. The Ommaya reservoir is inserted and is locked safely between the 
bone and the scalp (Fig 2.). Then, a catheter is threaded into the ventricle in the brain. Upon 
confirmation of placement, the scalp incision is closed. Intraoperative CT scans confirm 
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positioning and postoperative flow study must confirm unrestricted CSF flow prior to the first use 
of the reservoir.  
Confirmation of Ommaya Catheter 
Placement by flow study. Following 
intrathecal injection of 0.5 mCi of indium 111 
DTPA, serial whole-body anterior and 
posterior images are acquired at 30 minutes, 
4 hours, 20 hours and 24 hours. 
 
 
Fig 2: Ommaya reservoir  
 
 
Intrathecal IL-2 Treatment 
Treatment with IT IL-2 consisted of an induction and a maintenance phase for each patient. The 
planned induction phase was defined as a 4-week treatment period from the first IT IL-2 
injection. Recombinant IL-2 at1.2 million international units (mIU) in preservative-free water 
(volume ~ 0.3ml) was used and injected over less than 1 minute via Ommaya reservoir into the 
ventricle.  Treatments were administered daily for 5 days during the first week, and 2-3 times 
per week as tolerated for the additional 3 weeks. Patients remained hospitalized throughout the 
induction phase. If side effects consistent with increased intracranial pressure (ICP) (e.g., 
severe headache, uncontrolled nausea or vomiting, confusion, or other change in mental status) 
developed, CSF was removed via the Ommaya reservoir for symptomatic relief.  The maximum 
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CSF amount removed at any time was 20 cc, and when possible, CSF was removed at least 6 
hours after IT IL-2 instillation to avoid decreasing CSF IL-2 levels.64  
Scheduled IT IL-2 treatments were delayed or omitted if clinically indicated by uncontrolled 
symptoms or significant decline in performance status, and in such cases subsequent doses 
were reduced to 1.0 or 0.6 mIU at the treating physician’s discretion. Other supportive 
medications were provided scheduled (Tab. 2). Other as needed medication included tramadol, 
stool softener, especially if opioid analgesia was required, loperamide, hydromorphone, 
meperidine, prochlorperazine and lorazepam.  
Tab. 2 Scheduled medication during IT IL-2 induction 
Scheduled Medications Dose Route Dosing interval 
Acetaminophen 
650mg 
By mouth Start with IT IL-2, every 4 hrs 
Odansetron 8mg intravenous Start with IT IL-2, every 4 hrs 
Diphenhydramine 12.5mg 
intravenous 
Start with IT IL-2, every 6 hrs 
Metoclopramide 10 mg intravenous Start with IT IL-2, every 6 hrs 
 
Patients continued on a maintenance therapy schedule if they derived clinical benefit from 
treatment and were able to tolerate treatment. Maintenance treatment consisted of a single 
dose of IT IL-2 initially given weekly, then biweekly, and eventually extended to every 4-8 
weeks. Patients were admitted to the inpatient setting for these treatments, and were generally 
observed for 24 hours for signs/symptoms of elevated ICP, which were treated with CSF 
removal.  
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Assessments 
A comprehensive neurological examination was conducted prior to each administration of IT IL-
2. MRI of the brain and/or the entire spine was required every 4-8 weeks. MRI brain and spine 
imaging was repeated approximately 4-8 weeks after the first dose of IT IL-2, and positron 
emission tomography (PET) and/or computed tomography (CT) scans of the  chest, abdomen, 
and pelvis were used to evaluate extracranial disease. CSF samples underwent cytopathology 
evaluation for malignant cells, and cell counts, glucose and protein content were measured by 
the laboratories of the Division of Pathology and Laboratory Medicine at MD Anderson Cancer 
Center. If suspicious cells were seen on cytopathology review, immunocytochemistry with anti-
melanoma monoclonal antibody HMB-45 was used to confirm the presence of melanoma cells 
in the CSF.   
Statistical Methods and Analysis 
Data were collected retrospectively for each patient, including treatment characteristics, 
neurological symptoms, CSF characteristics, radiographic studies, extracranial disease status, 
and overall survival.  The Kaplan-Meier method was used to estimate the distribution of OS 
duration from the first IT IL-2 treatment.  The log-rank test was used to compare distributions.  
Cox proportional hazards regression was used to assess the association between OS duration 
and disease and demographic covariates of interest.   
For data analysis, the following patient and tumor characteristics were recorded: 
Demographics 
• DOB 
• Gender 
• Last Follow up  
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Tumor Melanoma information 
• Melanoma mutation status, including type of mutation 
• Cause of death related to LMD 
• Prior or concurrent treatments, disease status 
• Type of previous systemic therapies (chemotherapy, immunotherapy, targeted therapy) 
• Previous radiation to brain and/or spine 
• Concomitant therapies at start of IT IL-2 treatment 
• Sites of disease at start of IT IL-2 treatment 
• Previous brain metastasis present 
• Systemic disease controlled at start of IT IL-2 treatment 
• Parenchymal disease controlled at start of IT IL-2 treatment. 
• Performance status at start of IT IL-2 treatment 
• LDH level at start of IT IL-2 treatment 
• Neurological deficits present at start of IT IL-2 treatment 
• Patient receiving steroids at start of IT IL-2 treatment 
• CSF positive before induction period 
• CSF clearing during induction in a previously positive CSF 
• CSF turning positive during induction in a previous CSF negative 
Day of first IT IL-2 treatment 
• Opening pressure 
• CSF WBC with differential including histiocytes, lymphocytes, eosinophiles, basophiles) 
• CSF RBC 
• CSF protein and glucose levels 
• CSF sodium level  
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Other 
• Lowest CSF sodium levels during induction 
• Total number of  IL-2 doses during induction 
• Dose reduction during IT IL-2 induction period 
For survival analysis 
• Date of initial LMD diagnosis 
• Diagnosis based on CSF, MRI brain and/or spine, operating report 
• Date of last follow up 
• Date of death, if applicable 
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CHAPTER III 
RESULTS 
Patient Characteristics 
The outcomes of 43 MM patients with LMD initiated on IT IL-2 from August 2006 to July 2014 
were reviewed (Table 1).  Twenty-eight (65%) of the patients had both positive CSF cytology 
and radiographic evidence of LMD, three (7%) had positive cytology only and 11 (26%) had 
radiographic findings only.  One patient was diagnosed with LMD based on histopathological 
analysis of surgical specimen showing metastatic melanoma in the brain parenchyma as well as 
the dura without positive radiographic findings or CSF cytology. 
The median age at the start of IT IL-2 treatment was 46.7 years (range, 18.8-71.0), and the 
median serum LDH level was 500 (262-1826) IU/L (Table 3).  A total of 33 of the 43 patients 
(77%) had an ECOG performance status of 0-1.  Neurological deficits attributable to LMD were 
present in 21 (49%) patients. Four patients (9%) had LMD but no history of systemic melanoma.  
Among the remaining patients, eight (19%) had no evidence of active systemic disease at the 
time of IT IL-2 induction; 20 (47%) had stable systemic disease; and 11 (26%) had progressive 
systemic disease.  Previously treated or concomitant parenchymal brain metastases were 
present in 34 (79%) patients, including 17 with progressing parenchymal metastases.  
The majority (74%) of patients had received prior systemic therapy, which included BRAF and 
MEK inhibitors, temozolomide, and other chemotherapy agents. Twenty patients (47%) had 
received prior systemic immunotherapy, including ipilimumab, anti- PD-1 antibodies, adoptive 
cell therapy with tumor infiltrating lymphocytes (ACT TIL), and biochemotherapy.  
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Table 3: Demographics of LMD patients  
Variable Category N (%) 
   
Sex 
Male 32 (74%) 
Female 11 (26%) 
   
Mutation Status 
BRAF 21 (58%) 
NRAS 9 (25%) 
None 4 (25%) 
Other 2 (6%) 
Unknown 7 
   
Diagnosis Basis 
CSF Positive Only 3 (7%) 
Radiology Positive Only 11 (26%) 
Surgery Only 1 (2%) 
CSF And Radiology Positive 28 (65%) 
   
Prior Systemic Therapy 
No 11 (26%) 
Yes 32 (74%) 
   
Previous Temodar Therapy 
No 29 (67%) 
Yes 14 (33%) 
   
Prior Immunotherapy No 23 (53%) 
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Yes 20 (47%) 
   
Prior BRAF, BRAF/MEK 
Inhibitors 
No 33 (77%) 
Yes 10 (23%) 
   
Prior Radiation Therapy 
No 16 (37%) 
Yes 27 (63%) 
   
Steroids 
No 26 (60%) 
Yes 17 (40%) 
   
Previous Parenchymal 
Brain Mets 
No 9 (21%) 
Yes 34 (79%) 
   
LDH > ULN 
No 15 (35%) 
Yes 28 (65%) 
   
Neuro Symptoms 
No 22 (51%) 
Yes 21 (49%) 
   
Extracranial Disease 
None 8 (19%) 
LMD Only 4 (9%) 
Systemic Controlled 20 (47%) 
Systemic Uncontrolled 11 (26%) 
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Concomitant Medications 
None 27 (63%) 
Targeted 7 (16%) 
Other 9 (21%) 
 
IT IL-2 Treatment and Concomitant Therapies 
Patients received a median of nine IT doses of IL-2 during the induction period (range, 3-14). All 
patients developed toxicities from IT IL-2, including fever, chills and/or symptoms of elevated 
ICP, which included nausea and headache. Some patients experienced vomiting and temporary 
changes in mental status as well as deterioration of their performance status.  All patients 
required additional CSF drainage for symptom control and ICP relief during the induction period 
and received supportive medications as needed. In eight patients, CSF drainage had to be 
performed thrice on the same day as IT IL-2 administration. Almost half the patients (44%) 
required IT IL-2 dose reduction to either 1.0 mIU or 0.6 mIU during the induction phase. Five 
patients had shunts in place due to increased ICP or hydrocephalus, and four patients were 
converted to a shunt either during induction (n=3) or while on maintenance therapy. Despite this 
intensive therapy, no patients died of toxicity attributed to IT IL-2. 
Seventeen patients (40%) received concomitant corticosteroids with IT IL-2, with a median daily 
dexamethasone dose of 8 mg (range 1-24 mg).  Twenty-seven patients did not receive any 
concomitant anti-cancer therapy during IT IL-2 induction. Six patients received radiation therapy 
during the induction period, including stereotactic radiosurgery (SRS, n=1), focal sinonasal 
radiation (n=1), and whole brain radiotherapy (WBXRT, n=4).  Other patients continued 
systemic therapy that had been initiated prior to the first dose of IT IL-2, including ipilimumab 
(n=2); BRAF inhibitor (BRAFi) alone or in combination with MEK inhibitor (MEKi) or 
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temozolomide (n=7); temozolomide in combination with WBXRT (n=3); and biochemotherapy 
(n=1).  
 
Overall survival 
The median overall survival (OS) for all patients (n=43) treated with IT IL-2 from the start of 
treatment was 7.8 months (range, 4.7-16.3 months), with 1-, 2-, and 5-year OS rates of 36%, 
26%, and 13%, respectively (Figure 3). 
Patients with prior but no systemic disease or LMD with no prior or concurrent systemic disease 
(n=12) had a median OS of 20.2 months from the start of IL-2 treatment (range 1.7-90.8 
months) (Figure 3). Patients with concurrent but controlled systemic disease (n=20) had a 
median OS of 10.6 months (range, 0.5-47.0 months), while patients with progressive systemic 
disease (n=11) had a median OS of 4.3 months (range, 0.4-55.9 months, Fig. 4).  No significant 
difference in OS (p=0.21) was observed in patients with elevated LDH (Fig. 5), requiring 
steroids (Fig 6) or in patients with or without parenchymal brain metastases (controlled or 
uncontrolled, Fig 7). The presence of neurological symptoms (HR 2.1, p=0.03), positive CSF 
cytology prior to the start of treatment (HR 4.1, p=0.001), and concomitant use of targeted 
therapy (HR 3.0, p=0.02) was associated with shorter OS on univariate analysis (Table 4, 5).  
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Fig. 3: The overall 
survival (OS) for all 
patients (n=43) treated 
with IT IL-2 from the start 
of treatment.  
 
 
 
Fig .4 Impact of 
extracranial disease 
status on outcomes 
with IT IL-2 
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Fig. 5 Impact of 
serum LDH status 
on outcomes with 
IT IL-2 
 
 
Fig. 6 Impact of 
concurrent 
steroids use on 
outcomes with IT 
IL-2 
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t  
Fig. 7 Impact of 
parenchymal 
brain metastasis 
status on 
outcomes with IT 
IL-2 
 
 
 
Table 4: Associations of clinical factors with overall survival with IT IL-2 
Variable Level Total 
Total 
Deaths 
Median 
OS 
Hazard 
Ratio 95% CI 
P-
Value 
        
Age 
Per Year 43 35 7.8 1.001 0.97, 
1.03 
0.92 
        
Sex 
Male 32 26 5.9 ----- ----- ----- 
Female 11 9 9.6 0.93 0.43, 
1.99 
0.85 
        
LDH 
Normal 28 24 10.6 ----- ----- ----- 
Elevated 15 11 5.2 1.03 0.51, 0.93 
34 
 
2.12 
        
BRAF 
Mutation 
No 15 11 16.3 ----- ----- ----- 
Yes 21 17 10.6 1.42 0.66, 
3.04 
0.37 
Missing 7 7 * * * * 
        
Neuro 
Symptoms** 
No 22 16 11.7 ----- ----- ----- 
Yes 21 19 2.8 2.14 1.09, 
4.19 
0.03 
        
Dose 
Reduction 
No 24 18 11.8 ----- ----- ----- 
Yes 19 17 5.1 1.73 0.88, 
3.41 
0.11 
        
Total IL-2 
doses 
received 
during 
induction  
Per Dose 43 35 7.8 0.89 0.77, 
1.01 
0.08 
        
Extracranial 
Disease 
None/LMD 
Only 
12 9 20.1 ----- ----- ----- 
Systemic 
Controlled 
20 16 10.6 1.68 
0.73, 
3.85 
0.22 
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Systemic 
Uncontrolled 
11 10 4.3 2.57 
1.03, 
6.45 
0.04 
        
Concomitant 
Medications 
None 27 19 11.8 ----- ----- ----- 
Targeted 
7 7 4.7 3.02 
1.18, 
7.74 
0.02 
Other 
9 9 8.3 1.88 
0.82, 
4.34 
0.14 
        
Abbreviations used: IL-2, interleukin-2; LDH, lactate dehydrogenase; LMD, leptomeningeal 
disease; *: NA; **: at initiation of therapy 
Review of the death notifications and last visit/contact notes in the electronic medical record 
system was performed to determine whether LMD contributed directly to patient demise among 
those who died (n=35, and one lost to follow-up).  Death was attributable to LMD in 16 patients, 
and to overwhelming systemic disease or from complications arising from parenchymal brain 
metastases in 10 patients.  The cause of death was not specified for eight patients, but 
presumed due to melanoma.    
CSF clearance 
Thirty patients had positive CSF cytology prior to starting IT IL-2 treatment. Nine of these 
patients had CSF that became negative for melanoma cells during the induction period, and 
remained negative subsequently.  Conversion to a negative CSF cytology was not associated 
with significantly improved OS (HR 1.27, p=0.58) (Table 4).  
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Table 5: Association of CSF features with overall survival with IT IL-2 
Variable Level Total 
Total 
Deaths 
Median 
OS 
Hazard 
Ratio 95% CI P-Value 
        
Cytology at 
Diagnosis 
Negative 13 7 33.2 ----- ----- ----- 
Positive 30 28 5.1 4.09 1.72, 9.74 0.001 
        
CSF 
Clearing 
No 20 19 4.5 ----- ----- ----- 
Yes 9 8 9.3 0.98 0.42, 2.29 0.96 
Prev. 
Negative 
13 7 33.2 0.25 0.10, 0.61 0.002 
Missing 1 1 * * * * 
        
CSF Turning 
Positive 
During 
Induction 
No 7 3  ----- ----- ----- 
Yes 
6 4 16.2 2.26 
0.49, 
10.40 
0.29 
Missing 30 28 * * * * 
Abbreviations used: CSF, cerebrospinal fluid; *: NA 
Thirteen patients did not have melanoma cells on CSF examination at initiation of the IT IL-2. 
Twelve of these patients had MRI findings supporting the diagnosis of LMD, and one patient 
was found to have LMD during a craniotomy. During the IT IL-2 induction, six (46%) of these 
patients were detected to have developed positive CSF cytology.  All but one of these patients 
eventually converted to negative CSF cytology status during their maintenance phase. One 
additional patient with negative CSF cytology at baseline had melanin pigment detected in the 
CSF but no melanoma cells.  Among the other six patients with negative baseline CSF cytology, 
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only atypical cells were repeatedly detected in the CSF (examined volume ranging from 2-10 
ml), but staining and morphology did not confirm melanoma.  
 
Opening pressure, and CSF analysis 
Twelve patients (28%) had elevated ICP at initiation of IT IL-2, with recorded levels of up to 40 
cm H2O (normal ICP < 15 cm H20). Opening pressures ranged between 0-40 cmH2O. The 
median opening pressure was 11.5 cmH2O. Opening pressure increased in all patients during 
the induction treatment and on day 21, in patients whose opening pressures were recorded, the 
values ranged from 5- 60 cmH2O, with a median of 20 cmH2O. The median change between 
day 1 and day 21 opening pressure was 7 cmH2O. Baseline opening pressures (HR=1.03   95% 
CI= (0.99, 1.07), P=0.22), opening pressure on day 21 (HR=0.99   95% CI= (0.97, 1.02), 
P=0.59) and change in opening pressure while on treatment (HR=0.98   95% CI= (0.96, 1.01), 
P=0.19) were not associated with survival.  
While the total white blood cell count (WBC) in the CSF at baseline was not significantly 
associated with survival (p=0.59), the day 21 value of CSF WBC count was of marginal 
significance (HR=0.95 per 10 units, p=0.07), and the observed difference between baseline and 
day 21 levels was significant (HR= 0.97 per 10 units, p=0.03) (Table 6).  
Table 6: Association of CSF WBC with Survival 
Variable Level Total 
Total 
Deaths 
Median 
OS 
Hazard 
Ratio 95% CI 
P-
Value 
        
WBC: 
Baseline 
Per 10 Units 43 35 7.8 1.01 
0.97, 
1.05 
0.59 
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WBC: Day 
21 ** 
       
Per 10 Units 38 31 8.5 *** 0.95 
0.90, 
1.004 
0.07 
        
WBC: Day 
21-Baseline 
** 
Per 10 Units 38 31 8.5 *** 0.97 
0.95, 
0.997 
0.03 
       
        
 
Median level of protein in the CSF was 23 (range -1132) and median glucose level was 67 
(range 28-99). An elevated protein level in the CSF was considered to be > 55 mg/dL and was 
not associated with worse outcome (HR=1.75, 95% CI= (0.76, 4.04); P=0.18) in the 7 patients 
who had elevated baseline CSF protein levels.  
 
Transient Hyponatremia 
Transient hyponatremia during the induction phase was observed in most patients, and 
represented a toxicity that rarely required further intervention.  One patient continued to have 
transient hyponatremia with each maintenance dose, requiring 3-4 days of hospitalization after 
each maintenance dose until the neurological symptoms associated with his hyponatremia (gait 
instability, confusion and decreased mentation) resolved. His sodium levels are shown below in 
Figure 8. 
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Fig. 8  Transient hyponatremia as one of the adverse events observed with IT IL-2 
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CHAPTER IV 
DISCUSSION 
LMD is associated with an extremely poor prognosis in virtually all tumor types, including 
melanoma. The results reported here represent the largest known cohort of patients with LMD in 
which the safety and efficacy of IT immunotherapy have been evaluated to date in any type of 
cancer.  These results provide evidence that IT IL-2 therapy can produce long-term survival in 
selected metastatic melanoma patients with LMD, and provides proof-of-concept that IT 
immunotherapy may be an effective strategy for these patients. 
This study of IT IL-2 represents the largest cohort of melanoma patients with LMD evaluated for 
outcomes with a specific therapy reported to date, and with the longest follow-up for overall 
survival.  The demonstration of prolonged survival in a subset of these patients is a unique and 
important result, and one needs to be aware that this long-term survival observed is similar to 
the prolonged survival now repeatedly seen with immunotherapies. 65-67   While retrospective 
studies by our group and others support that the median survival of melanoma patients with 
LMD is generally < 2 months, the median OS in this cohort was 7.8 months.  Particularly 
impressive results were observed in patients with no prior history of non-LMD disease (median 
OS 19.6 months), and in patients with prior but no concurrent systemic disease (median OS 
20.2 months), who together comprised 28% of the patients in the study.  Relatively favorable 
results were also observed in patients with concurrent but controlled systemic disease (46% of 
patients, median OS 10.6 months).  In contrast, patients with uncontrolled systemic disease had 
a median OS of only 4.3 months.  Importantly, a subset of the patients treated with IT IL-2 
achieved durable OS, with 26% and 13% of the patients alive 2 and 5 years after the start of 
treatment, respectively.  We also recently reported the outcomes of 178 patients with metastatic 
melanoma and LMD, diagnosed at our institution between 2000 and 2015. The overall survival 
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for all patients was only 3 months. Such outcomes are essentially unprecedented in melanoma 
patients with LMD, and add to the expanding number of reports documenting durable OS in 
metastatic melanoma patients treated with immunotherapy. 68-69        
The presence of neurological symptoms has previously been identified as a negative prognostic 
factor in a number of outcome analyses of melanoma patients with CNS involvement. 70   Thus, 
neurological symptoms are likely prognostic and not predictive in patients with LMD receiving IT 
IL-2.  In this study, patients could be enrolled based on radiographic, CSF cytology, or surgical 
findings of LMD.  The observed improved outcomes in patients with negative CSF cytology 
raises questions as to the certainty of LMD diagnosis by MRI imaging alone.  However, 50% of 
the patients with negative cytology at baseline were eventually determined to have a positive 
cytology during the induction period, and several others had melanin and/or atypical cells 
identified.  The observed frequent conversion of CSF from negative to positive with treatment 
could be due to the serial sampling performed in this trial, as it is known that repeated 
cytological analysis increases the sensitivity of detection of malignant cells in CSF.4  
Alternatively, it is possible that the IT IL-2 treatment could cause cells to detach from the 
leptomeninges, allowing improved detection.  Notably, in patients with positive CSF cytology at 
baseline, there was no significant correlation between CSF clearance and OS.  Thus, along with 
the challenging nature of assessing radiographic responses in LMD 4, we believe that these 
findings support the use of OS as a primary endpoint in clinical studies in melanoma patients 
with LMD, and support the significance of the findings observed in this cohort of patients treated 
with IT IL-2.  The findings in this trial also support the need for the development of additional 
diagnostic methods on CSF to improve the ability to diagnose and to evaluate treatment 
responses in LMD patients in the future. 11 
Furthermore, our own review of all melanoma LMD patients seen at MD Anderson showed a 
similar association with above discussed factors and poor overall survival. Importantly, in both 
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studies, neither a history nor presence of concurrent parenchymal brain metastasis affected 
overall survival.  
Unfortunately, the performance status of patients receiving intrathecal IL-2 was not consistently 
evaluated, and therefore univariate analysis not possible. It should be mentioned thought that 
patients in general would have not been treated if they had an ECOG >2, because the 
anticipated significant toxicity from treatment required good baseline performance status. 
Neurological symptoms could be potentially a surrogate marker for LMD disease burden, and 
depending on type and location of CNS involvement, leading to further morbidity and worsening 
in the performance status.  Multiple studies, including our own, have shown that there is better 
outcome associated with better performance status, which ultimately might lead to more 
aggressive multidisciplinary treatment.  Fifteen of our patients had elevated LDH at treatment 
initiation, but unlike other reports, this had no impact on outcome.  
In contrast to other studies, elevated intracranial pressure and elevated CSF protein, which is 
often observed together in patients with LMD, did have no significant impact on survival. This 
might be due to overall still small number, with only 7 patients having elevated CSF protein 
levels.  
While changes in the CSF have been observed in the initial intrathecal IL-2 and interferon case 
reports, virtually nothing is known about the cell composition of the CSF at baseline and the 
changes of this “microenvironment” as response to intrathecal immunotherapy. This is the first 
study to report a change within the CSF leukocyte count to be associated with marginally 
improved survival. While this is not completely surprising based on the mechanism of action of 
IL-2, many questions remain open and will require further assessment. It remains unclear if the 
total cell count or the type of cells has a higher impact on survival. Initial flow cytometry of CSF 
leukocytes of a patient deriving benefit (responder) and a non-responder patient showed that 
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the cell population in the responder mainly consisted of T-cell (85%), the majority of which were 
CD8+ (68%) cells. In contrast, the nonresponder had a higher proportion of NKD cells (52%), 
while the T cells were predominantly CD4+ (73%) (unpublished data, TIL lab UT MDA). These 
findings are not surprising in light of recent publications uncovering differences in the tumor 
microenvironment, CD8+ infiltration and upregulation of genes leading to an inflamed 
microenvironment and responders to immunotherapy with either anti-CTLA4 or anti-PD1. While 
paucity of CSF cells and absence of true tumor tissue will make monitoring the CSF more 
challenging, further analysis is warranted.  These “liquid biopsies” could identify differences in 
the immune cell repertoire of patients with LMD and their response to intrathecal 
immunotherapy, and in exchange leading to strategies overcoming treatment resistance.  
Lack of treatment response could be due to just simply paucity of cells, and we attempted to 
overcome this by direct injection of tumor infiltrating lymphocytes into the CSF. 71 This is, to our 
knowledge, the first case report that described this approach, while another case report 
described the safe use of IT cytotoxic T cells. 71-72 Both of these reports are based on clinical 
experience with adoptive cell therapy using autologous TIL in conjunction with high-dose IL-2. 
73-74 Our patient, who initial diagnosis of cutaneous melanoma was 3 years prior, was diagnosed 
with stage IV disease in January 2010. After multiple lines of treatments, he developed lower-
extremity weakness and numbness of the lower extremities after requiring surgery for 
splenectomy and bowel resection. At this point, CNS imaging revealed LMD in the distal cord 
and nerve roots at the lumbar level. As the standard of care, he was started on IT IL-2, but 
unfortunately experienced progression of LMD both clinically and radiologically. Despite 
palliative radiation to the spine, he still experienced progression of LMD, but his systemic 
disease remained grossly stable.  
He then received IT tumor-infiltrating lymphocytes (TIL) under a compassionate-use 
investigational new drug application (CIND 10-0060) at the beginning of January 2011. He 
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received a total of three IT TIL injections, with doses of 0.3 x 109, 1 x 109 and 3 x 109 IT TIL. 
Each IT TIL dose was supported by IT IL-2, which was given twice weekly.   
While the patient eventually died 5 months later from systemic and parenchymal brain disease 
progression, it should be noted that his LMD remained stable in imaging and on clinical exam.  
 CSF was banked during this treatment and later retrospectively analyzed. One of the concerns 
related to administration of IT TIL was the development of a cytokine storm; while elevated 
levels of cytokines were found in the CSF, clinically the patient tolerated all three dose levels of 
IT TIL very well. 71  Based on this experience, I  hypothesize that the intrathecal administration 
of TIL can be safe and will improve the efficacy of IT IL-2, particularly as this approach could 
also overcome resistance to IT IL-2 caused by decreased trafficking of anti-tumor T cells into 
the CSF.  A clinical trial based on this concept is currently ongoing (NCI NCT00338377), and 
was developed based on the results of this thesis work.  
Despite these promising results, we acknowledge that the retrospective nature of this non-
randomized study imposes some inherent limitations on the interpretation of the results. All 
patients were treated under an institutional CIND, and additional treatments were administered 
at the discretion of the treating physician. None of these concomitant treatment approaches has 
been shown to prolong OS in patients with LMD, but a synergism cannot be excluded. While 
systemically administered BRAF inhibitors (BRAFi) have been shown to achieve clinical 
responses in a significant subset of melanoma patients with parenchymal brain metastases, 
concurrent targeted therapy treatment was associated with shorter OS in our cohort of patients 
with LMD.30  This finding was in contrast to a recently published retrospective review of 39 
melanoma patients with LMD.  While the full cohort had a median OS of only 1.7 months, 
patients who received treatment with either systemic therapy with targeted and/or 
immunotherapy had a median OS of 5.4 months. 12  While that study did not specify how many 
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patients had received therapy prior to the diagnosis of LMD, all 7 patients in our cohort that 
received concomitant BRAFi and IT IL-2 therapy developed (progressed with) LMD while taking 
BRAFi prior to the start of IT IL-2, supporting resistance to the targeted therapy at baseline.  
Two of these patients died within 3 weeks of IT IL-2 initiation from LMD progression.  One of 
these patients had a significantly elevated LDH level (1826 IU/L, range 265-1826) at time of IT 
IL-2 treatment initiation; both patients had markedly elevated opening pressures prior to the first 
dose of IT IL-2 (27 and 33 cm H20 respectively); and both patients had significant LMD burden. 
Thus, we postulate that the observed association of concurrent targeted therapy during the 
induction phase of treatment with shorter OS is most likely due to confounding factors, as 
opposed to a detrimental effect on the IT IL-2 treatment.  However, evaluation of additional 
patients, including patients without prior progression on targeted therapy, will be needed to 
confirm this. 
Another limitation of this study of IT IL-2 is that the retrospective nature of this cohort of patients 
treated on the basis of individual INDs also precludes detailed toxicity reporting and analysis.  
All patients developed toxicity during the induction phase and were hospitalized throughout that 
time for treatment and toxicity management. While unable to establish retrospective grading for 
the observed symptoms, they were likely similar in incidence and severity as previously 
presented by Papadopoulos et al in the initial description of the effects of IT IL-2. 39  That study 
reported chills (100% all grades, no grade 3), fever (98% all grades, 11% grade 3), nausea 
(95% all grades, 30% grade 3) and headache (99% all grades, 57% grade 3) as the most 
common clinical toxicities of IT IL-2.  The frequent and significant toxicity incurred by this 
regimen will likely limit its broad dissemination to cancer centers, similar to the experience with 
systemic IL-2 therapy.  Despite these challenges, our highly trained and motivated clinical team 
did not observe any treatment-related deaths with IT IL-2.  In addition, we generally observed a 
significant decrease in symptom burden in patients receiving intermittent maintenance therapy, 
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with only overnight observation required.  While the observation of prolonged survival in a 
subset of patients is very encouraging, the use of this therapeutic approach will be enhanced by 
the development of more robust predictors of clinical benefit.  Thus, further interrogation of 
clinical, molecular and immunological correlates of response and long-term OS is warranted.  In 
addition, our long-term outcomes also support the rationale to evaluate recently approved and 
experimental immunotherapies in patients with LMD, including those with IT administration.   
In conclusion, this study reports the outcomes of the largest cohort of metastatic melanoma 
patients with LMD receiving a specific therapeutic intervention to date.  Our results demonstrate 
that despite their historically dismal prognosis, a subset of metastatic melanoma patients with 
LMD treated with IT IL-2 achieve long-term survival.  Additional studies are needed to identify 
biomarkers that predict the clinical benefit of IT IL-2 so that patients who have the greatest 
chance of responding to this treatment can be identified and selected for this high-risk therapy in 
the future.  In addition to supporting the potential clinical benefit of this treatment, these results 
strongly support the rationale for additional clinical trials in this patient population.  Despite the 
tremendous advances that have been made in the field of melanoma in recent years, effective 
treatments and clinical trials for patients with LMD remain critical unmet needs.  Our results 
show that long-term survival can be achieved with IT immunotherapy, but additional clinical 
trials and translational research efforts are needed to further improve the outcomes of these 
patients. 
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Chapter V 
LIMITATIONS 
As outlined, the retrospective nature of this work prevents complete and graded toxicity 
reporting. While we used a descriptive approach, this does not enable us to further analyze 
toxicity data in association with survival. We therefore were obliged to use dose reduction and 
total number of IT IL-2 doses received as a surrogate for significant toxicity.  
Furthermore, only a few patients had CSF banked in our institutional melanoma tissue bank, 
thereby preventing retrospective analysis of CSF samples. This would have allowed us to better 
describe the changes in the immune cell population observed while patients were receiving IT 
IL-2, as well as potentially uncover the mechanism of resistance to this therapy.  
Finally, the diagnosis and response evaluation of LMD can be very challenging.  While the 
evaluation of CSF by cytology has remained the gold standard for LMD diagnosis, this approach 
lacks sensitivity, and repeated CSF evaluation is often required. 3-4, 75-76(3, 4, 75, 76)(Le Rhun, 
Taillibert, et al., 2013; Le Rhun, Tu, et al., 2013; Le Rhun et al., 2014; Tu et al., 
2015)3,4,75,763,4,74,753,4,74,753,4,74,753,4,74,75 As a consequence, often patients are diagnosed based on 
CNS imaging by MRI alone, and it is possible that the initial “clearing” of the CSF was due to 
lack of sensitivity. Thus, the development and validation of methods that can accurately 
diagnose and assess treatment responses and clinical benefit in patients with LMD will facilitate 
future clinical trials in these patients. Therefore, our upcoming clinical trial (described below in 
“Future Direction”) will prospectively use the RANO- LM criteria, which incorporate neurological 
examination, CSF cytology, and radiographic evaluation, although it has yet to be validated in a 
prospective clinical trial. Further, there is evidence in melanoma and other disease types that 
serial evaluation of mutations detected in tumor-derived cell-free DNA in the blood may serve as 
an alternative “liquid biopsy” to evaluate treatment responses, and to detect resistance (i.e. 
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circulating BRAFV600E mutations with BRAF inhibitor therapy). 11, 77-78 (11, 77, 78) (Li et al., 2016; 
Pan, Gu, Nagpal, Gephart, & Quake, 2015; Wang et al., 2015) 11,77,78 11,76,77 11,76,77  Recent data 
also support that mutations can be detected in cfDNA isolated from the CSF, but to date this 
approach has not been evaluated prospectively in patients with LMD receiving therapy. 
Therefore, any trial enrolling LMD patients should strive to incorporate these novel response 
and assessment tools.  
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Chapter VI 
FUTURE DIRECTIONS 
 
While these results provide the proof-of-concept that IT immunotherapy with IL-2 is feasible and 
may achieve long-term survival in patients with LMD, there is a strong rationale to explore other 
treatments that may have greater efficacy and less toxicity. The results are very encouraging, 
but much remains unknown, and as part of this project, additional new collaborations started. 
For example, we have increased our CSF banking efforts significantly, and most melanoma 
patients who are receiving work-up for LMD will have part of their initially obtained CSF stored in 
our MelCore, and therefore readily available for future testing. Furthermore, I have built the 
largest melanoma LMD database in the world, which will be invaluable to learn even more 
prognostic and predictive factors in the treatment of patients with LMD.  
Given that the CSF represents a microenvironment, with details about immune cell populations 
and their changes in regards to systemic and intrathecal therapy still largely unknown, efforts 
are undergoing to evaluate baseline CSF samples by CyTOF. Finally, I recognize the challenge 
of diagnosing LMD. While the evaluation of CSF by cytology has remained the gold standard for 
LMD diagnosis, this approach lacks sensitivity and repeated CSF evaluation is often required.  
In addition, there is a critical need to improve our understanding of the molecular features of 
LMD from melanoma.  There is growing evidence in melanoma and other cancers that serial 
evaluation of mutations detected in tumor-derived cell-free DNA may serve as an alternative 
“liquid biopsy” to evaluate treatment responses (i.e. circulating BRAFV600E mutations with BRAF 
inhibitor therapy) and molecular features.11  While most studies to date have evaluated cfDNA in 
blood, recent data supports the feasibility of this approach for CSF as well, including in samples 
in which malignant cells are not detected by traditional cytology (Fig.5).  Thus, in this clinical 
trial, and in our parallel treatment of patients with IT IL2 and IT TIL, there is an opportunity to 
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evaluate if mutational analysis of cfDNA can be a surrogate for clinical activity in patients with 
LMD.  Comparison of the mutations detected in cfDNA from the CSF to mutations detected in 
other disease sites, including the blood, in individual patients may also provide new insights into 
the molecular basis and pathogenesis of LMD.  
Nivolumab (Nivo) is a fully humanized blocking antibody against the PD-1 receptor, which is a 
critical checkpoint regulator on T cells.  Previous clinical trials in patients without CNS 
metastases have demonstrated that systemic Nivo achieves clinical responses in ~40% of 
metastatic melanoma patients, and that <10% of patients have to discontinue treatment for 
toxicity. As the systemic activity and toxicity of Nivo is superior to HD IL2, we hypothesize that 
IT Nivo treatment will be safe, immunogenic, and clinically beneficial in MM patients with LMD.  
We therefore developed a clinical protocol which has now received full IRB approval.  
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APPENDIX Tables: 
Table 7: Patient demographics, basis for LMD diagnosis, previous therapies received, LDH levels, steroids use and presence of 
neurological deficits at time of LMD diagnosis 
Patient # Gender 
1=male, 
2=female 
Mutation   
1=BRAF   
2=NRAS  
3=neg  
4=unknown 
or not done 
5=other 
CSF positive 
0=no, 1=yes 
CNS MRI 
imaging 
positive for 
LMD 0=no, 
1=yes 
Op report    
1=pos   
2=neg   
6=not done 
or no info  
Previous 
Systemic 
Therapy 
0=no, 1=yes 
Previous 
Radiation 
Spine/ Brain 
therapy 
0=no, 1=yes 
Previous 
Systemic 
Therapy 
with 
Temodar 
0=no, 1=yes 
Previous 
Systemic 
Therapy 
with BRAF 
and/or MEK 
inhibitor 
0=no, 1=yes 
Previous Systemic 
Therapy with 
Immunotherapy 
(Ipilimumab, IL-2, 
anti- PD1, 
Immunotherapy 
as part of 
Biochemo) 0 = no, 
1 = yes 
LDH above 
institutional 
limit 0=no, 
1=yes 
Neurological 
Deficits 
from LMD 
0=no, 1=yes  
Steroids at 
time of first 
IT IL-2, and 
dose 0=no, 
1=yes 
1 1 1 1 1 6 1 1 0 1 0 0 1 0 
2 1 1 1 1 6 1 1 1 1 1 1 1 1 
3 1 3 0 1 2 1 1 0 0 0 0 0 0 
4 1 2 1 1 6 1 1 0 0 0 0 0 0 
5 1 2 1 1 6 0 0 0 0 0 1 0 1 
6 1 1 1 1 6 1 0 0 1 1 0 0 0 
7 1 5 0 1 2 1 1 0 0 1 0 0 1 
8 2 1 1 1 6 1 1 1 1 0 0 0 0 
9 2 1 1 1 6 1 0 0 1 1 0 0 1 
10 2 2 0 1 1 0 1 0 0 0 0 0 0 
11 1 1 1 1 6 1 1 0 0 0 1 0 0 
12 1 1 1 0 6 1 1 1 0 1 1 1 0 
13 1 1 1 1 6 1 1 1 0 0 1 1 0 
14 1 4 0 1 6 1 1 1 0 0 1 0 0 
15 1 1 0 1 2 1 1 1 1 0 0 0 0 
16 2 4 1 1 6 0 1 0 0 0 0 1 0 
17 1 4 1 1 6 1 0 1 0 0 0 1 1 
2 
 
18 1 2 1 1 6 1 1 0 0 1 0 1 0 
19 1 4 1 1 1 1 1 1 0 0 0 1 0 
20 1 1 1 1 6 1 1 0 1 1 1 1 0 
21 1 2 1 1 6 1 1 0 0 1 1 1 1 
22 1 1 1 1 6 1 1 0 0 1 0 1 0 
23 1 3 1 0 6 0 0 0 0 0 0 1 0 
24 1 1 1 1 6 1 0 1 0 1 0 0 1 
25 1 2 0 1 6 0 1 0 0 0 0 0 1 
26 1 4 1 1 6 1 1 1 0 0 1 1 1 
27 1 3 1 1 6 1 1 1 0 1 1 1 1 
28 2 1 1 1 6 0 0 0 0 0 0 0 0 
29 1 1 1 1 6 0 0 0 0 0 0 0 1 
30 2 2 1 0 6 1 0 0 0 1 0 1 0 
31 2 2 0 1 6 1 1 1 0 1 1 0 1 
32 1 3 0 1 1 0 0 0 0 0 1 0 0 
33 2 1 1 1 6 1 0 0 0 1 0 1 1 
34 1 4 1 1 6 0 0 0 0 0 0 1 1 
35 1 1 0 1 6 1 1 0 0 1 0 0 0 
36 1 5 1 1 6 1 1 0 0 1 0 1 1 
37 1 2 0 1 6 1 1 1 0 1 1 1 0 
38 2 1 0 1 6 0 0 0 0 0 1 1 1 
39 2 1 1 1 6 1 0 0 1 0 0 0 0 
40 1 1 0 0 1 0 0 0 0 0 0 0 0 
41 1 1 1 1 6 1 1 0 1 1 0 0 0 
42 2 1 1 1 6 1 0 0 1 1 0 1 1 
43 1 4 1 1 6 1 1 1 0 1 1 0 0 
 
3 
 
Table 8: CSF opening pressures, protein and glucose in the individual patient  
 Opening Pressures CSF Cell composition, protein and Glucose 
Patient  
# 
Day 1  Day 21 WBC RBC Histiocytes Lymphocytes Eosinophils  Basophils   Other cells Protein Protein Day 
1 abnormal 
1=yes, 0=no 
(cutoff 55) 
Glucose 
1 26 23 1 675 9 71 NR NR 1 41 0 71 
2 27 27 8 3 27 67 NR NR 3 68 1 43 
3 15 37 13 600 13 56 21 NR NR 48 0 65 
4 11 55 4 48 6 73 NR NR 3 115 1 76 
5 14 16 0 40 25 75 NR NR NR 12 0 71 
6 11.5 32.5 3  18 6 20 2 NR 2 15 0 74 
7 5 5 2 40 10 81 4 NR NR 12 0 64 
8 8 8 0 193 45 55 NR NR NR 12 0 49 
9 3 28 0 0 13 36 NR NR 48 20 0 67 
10 7 52 0 10 45 45 NR NR NR 12 0 57 
11 13 5 13 12 33 50 NR NR 8 42 0 67 
12 11 17 0 18 6 25 NR NR 64 15 0 66 
13 3 7.5 2 330 1 14 NR NR 80 18 0 45 
14 11 23 1 573 56 33 NR NR NR 17 0 75 
15 8 13 2 265 24 73 NR NR 1 27 0 70 
16 13 18 0 0 22 71 3 NR 3 50 0 47 
17 14 20 1 184 32 61 NR NR 4 18 0 74 
18 12 35 3 26 10 26 NR NR 2 33 0 71 
19 14 27 15 67 50 39 NR NR 5 + 6% TC 120 1 54 
20 4 16 0 12 5 73 NR NR 9 + 10% 
TC 
23 0 73 
21 13 6 5  975 16 12 0 0 1 + 4% TC 56 1 57 
22 19 45 12 180 1 1 NR NR 1  73 1 77 
4 
 
23 30 45 14 31 19 79 NR NR 1 22 0 55 
24 17 20 1 27 48 37 NR NR 11 27 0 73 
25 5 8 0 4 57 43 NR NR NR 12 0 55 
26 5 7 0 0 22 40 1 NR 37 462 1 54 
27 8 12 5 4 12 74 NR NR 8 33 0 58 
28 6 20 1 80 10 17 NR NR 4 20 0 71 
29 15 16 0 39 75 25 NR NR NR 16 0 61 
30 16 25 5 19 10 86 NR NR 1 + 2% TC 12 0 64 
31 6 5 0 0 33 66 NR NR NR 12 0 79 
32 17 45 1 44 9 87 NR NR 2 24 0 77 
33 35 37 12 1550 2 7 1 NR 90 55 0 50 
34 1 17 506 69000 8 43 NR NR 5 1142 1 28 
35 9 16 2 18 14 85 1 NR NR 38 0 73 
36 15 15 0 1 29 68 NR NR 1 55 0 99 
37 11 45 0 65 47 44 NR NR 6 18 0 70 
38 0 16 0 7 43 57 NR NR NR 3 0 87 
39 7 30 93 93 14 39 NR NR 3 12 0 59 
40 4 20 6 1980  17 30 NR NR 1 54 0 94 
41 30 40 2 120 6 59 NR NR 5 19 0 55 
42 18 22 2 24 39 31 NR NR 28 47 0 39 
43 22 60 8 50 17 15 NR NR 5 23 0 68 
 
Table 8: Ongoing clinical trial for brain metastasis 
NCT Number Name of Study Treatment Phase Estimated 
Accrual 
Cancer 
type 
Patients with 
LMD 
allowed? 
Immunotherapy 
NCT02681549 Pembrolizumab Plus Bevacizumab for 
Treatment of Brain Metastases in 
Pembrolizumab plus 
Bevacizumab  
II 53 NSCLC, 
melanoma 
no 
5 
 
Metastatic Melanoma or Non-small Cell 
Lung Cancer 
NCT02886585 Pembrolizumab In Central Nervous 
System Metastases 
Pembrolizumab  II 102 Solid 
tumors 
yes 
NCT02085070 MK-3475 in Melanoma and NSCLC 
Patients With Brain Metastases 
Pembrolizumab II 64 NSCLC, 
melanoma 
no 
NCT02621515 Nivolumab in Symptomatic Brain 
Metastases (CA209-322) 
Nivolumab  II 70   yes 
NCT02460068 A Study of Fotemustine (FTM) Vs FTM 
and Ipilimumab  (IPI) or IPI and 
Nivolumab in Melanoma Brain 
Metastasis (NIBIT-M2) 
Fotemustine; 
Fotemustine and 
Ipilimumab;  
Ipilimumab and 
Nivolumab  
III  168 melanoma not mentioned 
NCT02374242 Anti‐PD 1 Brain Collaboration for 
Patients With Melanoma Brain 
Metastases (ABC) 
Nivolumab vs. 
Nivolumab with 
Iipilimumab  
II 76 melanoma concurrently 
with 
measurable 
brain 
metastases 
NCT02320058 A Study to Evaluate Safety and 
Effectiveness in Patients With Melanoma 
That Has Spread to the Brain Treated 
With Nivolumab in Combination With 
Ipilimumab Followed by Nivolumab by 
Itself (CheckMate204) 
Nivolumab plus  
Ipilimumab followed 
by Nivolumab 
monotherapy  
II 110 melanoma no 
Targeted Therapy  
NCT01978236 Dabrafenib/Trametinib, BRAF or BRAF 
AND MEK Pre-op With BRAF and MEK 
Post-op, Phase IIB, Melanoma With 
Brain Mets,Biomarkers and Metabolites 
Dabrafenib plus 
Trametinib 
II 30 melanoma no  
NCT02452294 Buparlisib in Melanoma Patients 
Suffering From Brain Metastases 
(BUMPER)  
Buparlisib II 22 melanoma no 
NCT02308020 A Phase 2 Study of Abemaciclib in 
Patients With Brain Metastases 
Secondary to Hormone Receptor 
Positive Breast Cancer, Non-small Cell 
Abemaciclib II 247 breast, 
NSCLC, 
melanoma 
yes 
6 
 
Lung Cancer, or Melanoma 
NCT01904123 A Phase I Trial of WP1066 in Patients 
With Recurrent Malignant Glioma and 
Brain Metastasis From Melanoma 
WP1066 I  33 melanoma, 
recurrent 
glioma 
not mentioned 
NCT02039947 Study to Evaluate Treatment of 
Dabrafenib Plus Trametinib in Subjects 
With BRAF Mutation-Positive Melanoma 
That Has Metastasized to the Brain 
Dabrafenib plus 
Trametinib 
II 120 melanoma no 
NCT02537600 Vemurafenib and Cobimetinib 
Combination in BRAF Mutated 
Melanoma With Brain Metastasis 
(CONVERCE) 
Vemurafenib plus 
Cobimetinib 
II 137 melanoma  no 
Radiation plus systemic therapy 
NCT02716948 Stereotactic Radiosurgery and 
Nivolumab in Treating Patients With 
Newly Diagnosed Melanoma Metastases 
in the Brain or Spine 
Nivolumab plus SRS Pilot 90 melanoma not mentioned 
NCT02097732 Ipilimumab Induction in Patients With 
Melanoma Brain Metastases Receiving 
Stereotactic Radiosurgery 
Ipililumab plus SRS II 40 melanoma only if SRS is 
considered for 
LMD 
NCT01703507 Phase I Study of Ipilimumab Combined 
With Whole Brain Radiation Therapy or 
Radiosurgery for Melanoma 
Ipilimumab plus 
WBRT 
II 24 melanoma not mentioned 
NCT02115139 GEM STUDY: Radiation And Yervoy in 
Patients With Melanoma and Brain 
Metastases (GRAY-B) 
Ipilimumab plus 
WBRT 
II 66 melanoma not mentioned 
NCT02858869 Pembrolizumab and Stereotactic 
Radiosurgery for Melanoma or Non-
Small Cell Lung Cancer Brain 
Metastases 
Pembrolizumab plus 
SRS 
Pilot 43 NSCLC, 
melanoma 
no 
NCT01721603 A Phase 2 Prospective Trial of 
Dabrafenib With Stereotactic 
Radiosurgery in BRAFV600E Melanoma 
Brain Metastases 
Dabrafenib plus 
SRS 
II 39 melanoma  not mentioned 
 
